ATG4A Antikörper (AA 82-111)

Produktnummer ABIN1882158

Produktdetails anti-ATG4A Antikörper

Target: ATG4A (Autophagy related 4A Cysteine Peptidase (ATG4A))

Bindungsspezifität: AA 82-111

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser ATG4A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This ATG4A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 82-111 amino acids from human ATG4A.

Klon: RB7553

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000. IHC-P: 1:50~100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-ATG4A Antikörper (ABIN1882158)

Guo, Zhou, Gao, Zhang, Wei, Hong, Chu, Duan, Zhang, Xu: "MicroRNA-144-3p inhibits autophagy activation and enhances Bacillus Calmette-Guérin infection by targeting ATG4a in RAW264.7 macrophage cells." in: PLoS ONE, Vol. 12, Issue 6, pp. e0179772, (2017) (PubMed).

Li, Hou, Wang, Chen, Shao, Yin: "Kinetics comparisons of mammalian Atg4 homologues indicate selective preferences toward diverse Atg8 substrates." in: The Journal of biological chemistry, Vol. 286, Issue 9, pp. 7327-38, (2011) (PubMed).

Shintani, Klionsky: "Autophagy in health and disease: a double-edged sword." in: Science (New York, N.Y.), Vol. 306, Issue 5698, pp. 990-5, (2004) (PubMed).

Details zu ATG4A

Target: ATG4A (Autophagy related 4A Cysteine Peptidase (ATG4A))

Andere Bezeichnung: ATG4A (ATG4A Produkte)

Synonyme: apg4a antikoerper, autl2 antikoerper, F6E13.27 antikoerper, APG4A antikoerper, zgc:111958 antikoerper, Aut2a antikoerper, AUTL2 antikoerper, AI627006 antikoerper, AV169859 antikoerper, Apg4a antikoerper, Atg4al antikoerper, Autl2 antikoerper, Atg4a antikoerper, autophagy related 4A cysteine peptidase L homeolog antikoerper, autophagy related 4A cysteine peptidase antikoerper, Peptidase family C54 protein antikoerper, ATG4 autophagy related 4 homolog A (S. cerevisiae) antikoerper, autophagy related 4A, cysteine peptidase antikoerper, atg4a.L antikoerper, ATG4A antikoerper, AT2G44140 antikoerper, atg4a antikoerper, Atg4a antikoerper

Hintergrund: Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4A is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes. Preferred substrate is GABARAPL2 followed by MAP1LC3A and GABARAP.

Molekulargewicht: 45378

NCBI Accession: NP_443168, NP_840054

UniProt: Q8WYN0

Pathways: Autophagie